Friday 11th February 2022 |
Text too small? |
Blis Technologies Limited announces the interim results (unaudited) for the third quarter ending 31 December 2021.
Revenue for Q3 FY22 was $2.3m, with an EBITDA loss of $0.4m. Q3 FY22 revenue was down $0.1m compared with the same period last year but has increased $0.2m over Q2 FY22. The trends evident in the half year result were also reflected in the third quarter result.
Compared with the same quarter last year, there was a 42% increase in finished product sales with growth in our BLIS webstore (which includes Skincare sales) and the launch into the Canadian market, which partially offset a decline in ingredient sales.
The Q3 FY22 EBITDA loss of $0.4m is in line with forecast and reflects further early investment in our key new market initiatives, the Canada and Skincare launches which represent important future growth drivers.
We reaffirm our existing market guidance of revenue between $8.6m and $9.1m with an EBITDA deficit in the range of $2.3m to $2.7m.
Please see the link below for details
Third quarter performance update
Source: Blis Technologies Limited
No comments yet
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b